Acme United二季度电话会显示销售增长但盈利改善有限，Med-Nap认证目标年底完成

Earnings Call Insights: Acme United Corporation (ACU) Q2 2026
“Acme United made progress during the second quarter of 2026,” said Walter Johnsen (Chairman of the Board & CEO), highlighting that “net sales increased from $54 million to $63 million, an increase of 16%,” while “net income increased from $4.8 million to $5.1 million and earnings per share increased 5% to $1.22.”
Johnsen framed integration of the January 2026 acquisition as the central execution item: “My Medic sales in the second quarter were approximately $4.3 million with break-even operations, as expected,” and management is working “to increase the core direct-to-consumer business as well as expand the product offering to retail,” while also “consolidating freight with other Acme United shipments to reduce costs, and eliminating duplicate corporate functions.” He added: “The intention is to have strong profits from My Medic during all quarters with particular strength in the fourth quarter.”
Paul Driscoll (VP, CFO, Secretary & Treasurer) said, “Acme’s net sales for the second quarter were $62.7 million compared to $54 million in 2025, an increase of 16%,” adding that “excluding My Medic, sales increased 8%,” and that “the higher SG&A was primarily due to the addition of the My Medic business.”
On supply assurance, Johnsen said, “When the war with Iran began, we placed orders for approximately $10 million of extra inventory to buffer potential product shortages and cost increases,” adding, “we continue to maintain this extra level of stock and are positioned to address issues should they arise.”
Johnsen positioned the near-term setup as driven by mix, promotions, and easing tariff effects: “As we look to the coming quarters, we see continued growth of the first aid and medical business,” plus “resumption of promotional retail activity with our Westcott cutting tools,” “improving profitability at My Medic,” and “strengthening of our gross margins as high tariff products are replaced by lower cost ones.”
On timing of tariff-driven margin recovery, Johnsen said, “as we go through the rest of the year we will recover that 1%,” while also noting other pressures: “the freight has increased,” and “the dollar has weakened against the Chinese currency in the past year.”
Compared with Q1, management’s timeline language shifted from “a return to normal levels in the third quarter” (Q1) to “we expect the impact to lessen over the next two quarters” (Q2), per Driscoll’s prepared remarks.
Driscoll reported profitability and mix effects alongside higher operating spend: “The gross margin was 42.6% in the second quarter of 2026 compared to 41% in 2025,” while “SG&A expenses for the second quarter of 2026 were $19.9 million or 32% of sales compared with $15.8 million or 29% of sales for the same period of 2025.”
Driscoll cited the quarter’s earnings details: “Net income for the second quarter of 2026 was $5.1 million, or $1.22 per diluted share, compared to a net income of $4.8 million, or $1.16 per diluted share.” For year-to-date, he said, “net income for the first six months… was $6 million, or $1.46 per diluted share compared to $6.4 million, or $1.57 per diluted share.”
On leverage and cash generation, Driscoll said, “net debt increased… to $27.3 million at June 30th, 2026,” while also stating, “we generated approximately $15 million in free cash flow,” and reiterating acquisition and investment uses including “$14 million for the acquisition of the assets of My Medic” and “a cutting and sharpening line of products in Germany for $1.6 million.”
Timothy Call, The Capital Management Corporation: Asked whether Spill Magic, Med-Nap throughput, and certification to expand sales to “government and hospital systems” are long-term initiatives; Chairman Johnsen: “Those are long-term initiatives,” adding, “the certification work is progressing well and we should be done with it by year end,” and noting My Medic’s performance: “My Medic business in general has grown about a third this year.”
Timothy Call, The Capital Management Corporation: Asked for mix of healthcare vs. cutting tools; Chairman Johnsen: “health care is about 70% of the revenues right now,” while adding on Westcott, “we’ve got a full book of promotional activity for back-to-school.”
Georgy Vashchenko, Freedom Broker, Research Division: Asked drivers of record gross margin and the tariff impact; Chairman Johnsen: “My Medic has bigger gross margins than our regular business, but they spend it… in advertising,” and said “margins this quarter were reduced by about 100 basis points due to tariffs,” while CFO Driscoll added, “it’s probably 150 basis points,” and “most of the increase in gross margin… is due to the mix of My Medic.”
Jim Marrone, Singular Research: Pressed on consumer appetite and back-to-school demand; Chairman Johnsen: “so far those sales are right on plan, and we’re not seeing weakness,” and on Westcott shipments, “through June, it’s a record for us, just flat out record.”
Jim Marrone, Singular Research: Asked what is driving product preference; Chairman Johnsen said Westcott has “utility patents” and “world-class pricing,” and in first aid, “we’ve got a strong sourcing team for components in Asia… and that’s why we win at places like Walmart and at Grainger and at Fastenal.”
Richard Dearnley, Longport Partners, L.P.: Questioned why My Medic is largely DTC and asked about seasonality; Chairman Johnsen: “it’s built half a million social media followers,” and “this is mostly direct-to-consumer today,” while CFO Driscoll added, “it’s probably like 35% of the sales of the fourth quarter of the year.”
Jake Patterson, Talanta Investment Group: Asked price vs. volume in Westcott; Chairman Johnsen: “Most of it was volume.”
Analysts were slightly positive to positive, repeatedly praising results while probing margin drivers and demand durability, including “gross margin reached a record level” (Vashchenko) and concerns about “consumer… discretionary in their spending” (Marrone).
Management tone was slightly positive in prepared remarks and remained steady in Q&A, using confident framing such as “we’re excited about the place we’re at now,” while acknowledging pressures with statements like “the individual consumer is being pressed, but we’re not seeing it yet.”
Versus Q1’s “difficult first quarter,” Q2 language shifted toward execution and recovery, with more emphasis on promotional normalization and integration benefits, while tariffs remained a recurring qualifier in both quarters.
Q2 emphasized tangible recovery in profitability and promotions versus Q1’s tariff-driven earnings pressure, with Johnsen moving from “we expect to run through these items during the second quarter” (Q1) to describing an “improvement from the first quarter” and “continued gross margin expansion” (Q2).
Analyst focus broadened in Q2 toward consumer demand sensitivity, Canada softness, and gross margin composition, while Q1 questions leaned more heavily into Med-Nap remediation costs, CapEx, and the magnitude of tariff-driven margin impacts.
Management’s strategic through-line was consistent across both calls—retail expansion for My Medic, automation/capacity projects, and preparedness inventory—while Q2 added more specific commercialization timing, including “about to be going out to early distributors” for the next-generation compliance software.
Driscoll cautioned about “continued high inflation, high interest rates, and the imposition of new tariffs or changes [to] existing tariff rates,” and noted that the company has “experienced supply chain disruptions.”
Johnsen pointed to cost and macro risks that could pressure margins, including “freight has increased” and currency headwinds, while using the $10 million incremental inventory as a mitigation: the company is “positioned to address issues should they arise.”
In Q&A, Marrone raised the risk of weakening consumer demand, while Johnsen responded that “we’re not seeing it yet,” citing robustness in Europe and strength in shipments and backlog.
Management portrayed Q2 as a step-up quarter with higher sales and improved earnings, while reiterating that My Medic’s high-margin model comes with elevated advertising spend and seasonality that concentrates sales in Q4. Across prepared remarks and Q&A, the company stressed ongoing integration actions (sourcing, freight consolidation, and eliminating duplicate functions), expected tariff-driven gross margin recovery over the rest of the year, and continued investment in capacity and compliance initiatives, including a stated goal to complete Med-Nap certification work by year end and expand My Medic’s reach into retail and institutional channels.